本文已被:浏览 206次 下载 242次
Received:September 22, 2023 Published Online:June 20, 2024
Received:September 22, 2023 Published Online:June 20, 2024
中文摘要: 冠状动脉粥样硬化性心脏病(冠心病)是目前我国乃至世界范围内导致居民死亡的重要原因。在我国范围内冠心病的患病率正逐年上升。在导致冠心病发生的诸多原因中,血脂异常尤其是低密度脂蛋白胆固醇(LDL-C)升高尤为重要,在流行病学、遗传学以及临床研究中,均已证实其在冠心病发生发展中发挥重要作用。因此有效地控制LDL-C水平已成为预防冠心病发生、降低死亡率的重中之重。前蛋白转化酶枯草溶菌9(PCSK9)抑制剂作为新型的降脂药物可以很好的降低LDL-C,对预防不良心血管事件(MACEs)发生发挥重要作用。本文将对PCSK9抑制剂在冠状动脉硬化相关临床治疗问题上进行综述。
中文关键词: 前蛋白转化酶枯草溶菌9抑制剂 冠状动脉粥样硬化性心脏病 低密度脂蛋白胆固醇 心血管事件
Abstract:Coronary heart disease (CHD) is currently an important cause of mortality among residents in China and worldwide. The incidence of CHD in China is increasing annually. Among the various factors leading to the occurrence of CHD, abnormalities in blood lipids, especially elevated low-density lipoprotein cholesterol(LDL-C), are particularly significant. Epidemiological, genetic, and clinical studies have confirmed its crucial role in the development of CHD. Therefore, effectively controlling LDL-C levels has become paramount in preventing the onset of CHD and reducing mortality rates. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as novel lipid-lowering medications, effectively lower LDL-C and play a significant role in preventing major adverse cardiovascular events(MACEs). This article provides a review of PCSK9 inhibitors in clinical treatment related to coronary artery atherosclerosis.
keywords: Proprotein convertase subtilisin/kexin type 9 inhibitors Coronary heart disease Low-density lipoprotein cholesterol Cardiovascular events
文章编号: 中图分类号:R543.3 文献标志码:A
基金项目:内蒙古自治区自然科学基金(2019MS08022)
引用文本: